GSK3B and Parkinson disease: The data from preclinical and clinical studies produced promising results in combating PD with the use of WNT1, WNT2, WNT3, WNT31, WNT 8, and WNT8a agonists and GSK-3β inhibitors and DKK1 inhibitors.